iNtODEWORLD | FDA Bacteriophage Workshop
17120
single,single-post,postid-17120,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-5.1.1,vc_responsive
 

FDA Bacteriophage Workshop

The Food and Drug Administration (FDA), Center for Biologics Evaluation and Research, and the National Institutes of Health, National Institute of Allergy and Infectious Diseases held a public workshop entitled “Bacteriophage Therapy: Scientific and Regulatory Issues.” The purpose of the public workshop is to exchange information with the medical and scientific community about the regulatory and scientific issues associated with bacteriophage therapy.

The public workshop brought together government agencies, academia, industry, and other stakeholders involved in research, development, and regulation of bacteriophages intended for therapeutic use in humans. iNtRON Biotechnology also attended the workshop to discuss the scientific and regulatory considerations for bacteriophage therapies and to provide a forum for the exchange of information and perspectives, with the ultimate goal of facilitating development and rigorous clinical assessment of bacteriophage therapy products.

iNtRON has been securing a bacteriophage library for ‘‘Serious & Life-Threatening Infection’ and Intellectual Property (IP) to be prepared and be ready for the human bacteriophage market. As a leading company in the bacteriophage industry for animal-use, we will utilize our experience and know-how from the animal bacteriophage business for the human market and keep our global presence as a ‘Global Leading Company.’

It is iNtRON.



iNtODEWORLD, Inc is the US subsidiary of iNtRON Biotechnology, Inc.